End-capped -helices as modulators of protein function
Vilsbll has received personal honoraria for consulting, lectures and/or for advisory board participation within the last 36 months from Amgen, AstraZeneca, Boehringer-Ingelheim Pharmaceuticals, Bristol-Myers Squibb, Eli Lilly, Janssen-Cilag, Merck Sharp & Dohme, Novo Nordisk, Sanofi-Aventis, and Zealand Pharma and has received unrestricted research grants from Novo Nordisk and the Novo Nordisk Foundation
No significant difference was detected between the groups in the prevalence of cancer types, except for thoracic cancer (19.4% in the immune-related adverse events group vs 45% in the no immune-related adverse events group
GLP1 receptor agonists have changed the way we treat type 2 diabetes and obesity, offering powerful glucose-lowering effects and sustained weight loss